IBA Signs Deal With China Gold Irradiation To Install Rhodotron System

Ion Beam Applications (IBA) has signed a contract with China Gold Irradiation to install a Rhodotron TT1000 X-ray system at a new irradiation center in Jiaxing, Zhejiang; the TT1000—which typically costs €12–15 million—offers capacity comparable to a five-million-curie cobalt gamma facility and can process over 60,000 pallets a year. The Jiaxing site will be the region's first X-ray-equipped center, expanding sterilization capacity for a medical-device hub and industries such as biologics and traditional Chinese medicine at a time when cobalt supply constraints are accelerating adoption of X‑ray as a sustainable alternative, and IBA says it will invest further to meet diversified industrial demand. IBA shares closed down 0.36% at €11.10 on the Brussels exchange.

Analysis

Ion Beam Applications (IBA) has signed a contract with China Gold Irradiation to install a Rhodotron TT1000 X-ray system at a new irradiation center in Jiaxing, Zhejiang, marking the region's first X-ray-equipped facility; the TT1000 offers capacity comparable to a five-million-curie cobalt gamma center, can process more than 60,000 pallets annually, and typically costs €12–15 million. The facility targets sterilization demand from a local medical-device hub and adjacent industries such as biological products and traditional Chinese medicine, addressing heightened interest in X-ray alternatives amid cobalt supply constraints. IBA states it will invest further in X-ray systems to meet growing and diversified industrial demand, which suggests potential for follow-on orders and a larger addressable market for installations and associated service contracts. Market reaction to the announcement was muted, with IBA shares closing down 0.36% at €11.10, implying the news is positive operationally but not yet a material shift in near-term cash flow; primary risks remain execution of installations, timing of revenue recognition, and conversion of expressed demand into firm contracts in China.

Key Decisions for Investors

• Consider selective exposure to IBA on the thesis of structural sterilization demand in China driven by cobalt constraints, but size positions modestly given single-installation visibility.
• Monitor IBA announcements and the order pipeline for additional Rhodotron contracts and explicit capex commitments, as these will be the primary near-term catalysts for revenue and margin expansion.
• Track sterilization demand indicators in the medical-device, biologics and traditional Chinese medicine sectors and cobalt supply dynamics as leading signals for accelerated X-ray adoption.
• Manage execution risk by watching installation timelines, regulatory approvals, and any guidance on service/recurring revenue; consider hedges or position limits until multiple installations are contracted and revenue visibility improves.